<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00522639</url>
  </required_header>
  <id_info>
    <org_study_id>06-02-117</org_study_id>
    <secondary_id>TACIR</secondary_id>
    <nct_id>NCT00522639</nct_id>
  </id_info>
  <brief_title>Predictive Value of FDG-PET-CT Scans for Patients With Lung Cancer Receiving Concurrent Chemo-Radiation</brief_title>
  <acronym>FDG-PET lung</acronym>
  <official_title>Determination of the Predictive Value of FDG-PET-CT Scans, Blood Proteins and Blood Cells for the Prognosis for Patients With Lung Cancer Receiving Concurrent Chemo-Radiation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Maastricht Radiation Oncology</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Academisch Ziekenhuis Maastricht</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Maastricht Radiation Oncology</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of the study is to investigate the evolution ofn 18F-deoxyglucose (FDG) uptake&#xD;
      and the tumour characteristics determined in the plasma of patients with lung cancer of&#xD;
      during and after concurrent radiotherapy and chemotherapy&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This translational research part is aiming to give more insights in the way radiation injury&#xD;
      and tumour response develops.&#xD;
&#xD;
      It involves three parts:&#xD;
&#xD;
        1. Repetitive FDG-PET-CT scans in order to assess early tumour response monitoring.&#xD;
&#xD;
        2. Blood sampling before, during and after radiotherapy in order to find predictors for&#xD;
           normal tissue injury and for tumour response.&#xD;
&#xD;
        3. Extra staining of tumour biopsies&#xD;
&#xD;
      The FDG-PET-CT scan with i.v. contrast gives information of the tumour metabolism and its&#xD;
      morphology. Therefore, one extra FDG-PET-CT scans will be done during radiotherapy at day 8.&#xD;
      Tumour response will be determined by FDG-PET-CT scans 3 months after radiotherapy.&#xD;
&#xD;
      Blood samples&#xD;
&#xD;
        1. Before radiotherapy, 12 millilitres of blood (EDTA tubes) will be taken according to&#xD;
           serum protocol (appendix 5).&#xD;
&#xD;
        2. At day 7, day 14 during concurrent chemo-radiation, 7 days after the end of this&#xD;
           treatment and 3 months and 9 months after the end of radiotherapy, 12 millilitres serum&#xD;
           (EDTA tube) will be taken to investigate the evolution of the proteins [In the first&#xD;
           place, plasma concentrations of osteopontin and soluble CA9 for hypoxia, CRP and IL-6&#xD;
           for inflammation, total and free VEGF for angiogenesis and total and cleaved cytokeratin&#xD;
           18 for necrosis/apoptosis will be determined] during and after treatment, for its&#xD;
           kinetics may be important as predictive factors. Standard ELISA tests will be used to&#xD;
           determine these levels.&#xD;
&#xD;
        3. Before radiotherapy, at day 7 and at day 14 during radiation, 7 days after the end of&#xD;
           this treatment and 3 months and 9 months after the end of radiotherapy, 24 millilitres&#xD;
           of blood (EDTA tubes) will be taken to investigate the evolution of circulating cells&#xD;
           and their progenitors during and after treatment.&#xD;
&#xD;
      The tumour biopsies may be stained with markers for proliferation (e.g. KI 67), apoptosis&#xD;
      (e.g. M30), hypoxia (e.g. CA 9, Glut 1 and 3) and others (e.g. EGFR and EGFRvIII), in order&#xD;
      to correlate these measurements with response.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Poor accrual&#xD;
  </why_stopped>
  <start_date>October 2008</start_date>
  <completion_date type="Actual">June 2009</completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Tumour response, measured with FDG-PET-CT scans 3 months post-radiation. as a function of delta FDG uptake the first week during radiotherapy</measure>
    <time_frame>9 months post-radiation</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>- Incidence of acute radiation-induced oesophagitis - Incidence of radiation-induced pulmonary toxicity 3 and 9 months post-radiation</measure>
    <time_frame>9 months post-radiation</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Lung Cancer</condition>
  <condition>SCLC</condition>
  <condition>NSCLC</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>18F-deoxyglucose (FDG)</intervention_name>
    <description>contrast medium</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histological proven non-small cell or small cell lung cancer UICC stage I-III (in case&#xD;
             of small cell lung cancer: limited stage)&#xD;
&#xD;
          -  WHO performance status 0-2&#xD;
&#xD;
          -  Less than 10 % weight loss the last 6 months&#xD;
&#xD;
          -  In case of previous chemotherapy, concurrent chemo-radiotherapy can start after a&#xD;
             minimum of 21 days after the last chemotherapy course&#xD;
&#xD;
          -  No recent (&lt; 3 months) severe cardiac disease (arrhythmia, congestive heart failure,&#xD;
             infarction)&#xD;
&#xD;
          -  No active peptic oesophagitis&#xD;
&#xD;
          -  Life expectancy more than 6 months&#xD;
&#xD;
          -  Measurable cancer&#xD;
&#xD;
          -  Willing and able to comply with the study prescriptions&#xD;
&#xD;
          -  18 years or older&#xD;
&#xD;
          -  Not pregnant and willing to take adequate contraceptive measures during the study&#xD;
&#xD;
          -  Have given written informed consent before patient registration&#xD;
&#xD;
          -  No previous radiotherapy to the chest&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Not non-small cell or small cell histology, e.g. mesothelioma, lymphoma&#xD;
&#xD;
          -  Malignant pleural or pericardial effusion&#xD;
&#xD;
          -  History of prior chest radiotherapy&#xD;
&#xD;
          -  Recent (&lt; 3 months) myocardial infarction&#xD;
&#xD;
          -  Uncontrolled infectious disease&#xD;
&#xD;
          -  Distant metastases (stage IV)&#xD;
&#xD;
          -  Patients with active peptic oesophagitis in the last year&#xD;
&#xD;
          -  Less than 18 years old&#xD;
&#xD;
          -  Pregnant or not willing to take adequate contraceptive measures during the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dirk De Ruysscher, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>MAASTRO, Maastricht Radiation Oncology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Maastricht Radiation Oncology, MAASTRO</name>
      <address>
        <city>Maastricht</city>
        <state>Limburg</state>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>June 2009</verification_date>
  <study_first_submitted>August 29, 2007</study_first_submitted>
  <study_first_submitted_qc>August 29, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 30, 2007</study_first_posted>
  <last_update_submitted>June 29, 2009</last_update_submitted>
  <last_update_submitted_qc>June 29, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 30, 2009</last_update_posted>
  <responsible_party>
    <name_title>Dr. D.K.M. De Ruysscher</name_title>
    <organization>MAASTRO clinic</organization>
  </responsible_party>
  <keyword>lung cancer</keyword>
  <keyword>FDG-PET-CT</keyword>
  <keyword>blood proteins</keyword>
  <keyword>prognose</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Deoxyglucose</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

